anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The endothelial glycocalyx (EG) undergoes early degradation in sepsis. Our recent work introduced a novel therapeutic approach involving liposomal nanocarriers of preassembled glycocalyx (LNPG) to restore EG in lipopolysaccharide (LPS)-induced sepsis model of mice. While short-term effects were promising, this study focuses on the long-term impact of LNPG on mouse cerebral microcirculation. Utilizing cranial window, we assessed the stability of vascular density (VD) and perfused boundary region (PBR), an index of EG thickness, over a five-day period in normal control mice. In septic groups (LPS, LPS + 1-dose LNPG, and LPS + 2-dose LNPG), the exposure of mice to LPS significantly reduced VD and increased PBR within 3 h. Without LNPG treatment, PBR returned to the normal control level by endogenous processes at 48 h, associated with the recovery of VD to the baseline level at 72 h. However, mice receiving LNPG treatment significantly reduced the increment of PBR at 3 h. The therapeutic effect of 1-dose LNPG persisted for 6 h while the 2-dose LNPG treatment further reduced PBR and significantly increased VD at 12 h compared to LPS group. This study provides valuable insights into the potential therapeutic benefits of LNPG in mitigating EG degradation in sepsis.
Aqueous detergent mixtures containing - relative to solids content - a) 5-20 % by wt. alkyl and/or alkenyl oligoglycosides, b) 25-40 % by wt. alkyl sulfates. c) 35-60 % by wt. alkyl ether sulfates and d) 5-20 % by wt. amphoteric or dual ionic surfactants have synergistic effects in their washing, rinsing, foaming and cleansing power and in the way they are tolerated by the skin. They are therefore particularly well-suited for a multitude of surface active agents, especially hand dish-washing agents.
PURPOSE:To provide a preventive and remedy for nephritis, composed of a fat emulsion containing PGE1 or its derivative, capable of significantly suppressing the deposition of fibrin to glomerulus and the production of ascites and useful as a causal treatment agent for nephritis. CONSTITUTION:PGE1 or its derivative is added to a fat emulsion composed mainly of e.g. 5-50W/V% soybean oil, 1-50pts. of phospholipid (based on 100pts. of soybean oil) and a proper amount of water, and the produced PGE1 fat emulsion is used as a preventive and remedy for nephritis. The PGE1 fat emulsion is effective to nephritis, especially to prevent the prolongation, cicatrization and hyalinization of disease including the fibrin deposition to glomerulus. The deposition of fibrin to glomerulus plays an important role on the prolongation of nephritis, and according the agent is effective for the prevention of chronic nephritis. Dose: about 0.1-10mug/kg of PGE1 or its derivative per dose and 1-2 doses daily.
The invention relates to medicine and can be used for protecting a human being against bacteria or viral infections. The inventive dermatic is embodied in the form of a soap, shampooing, gel or a cream. Anti-infective preparations for example dioxidine in a liposomal form and in a subtherapeutical dosage, for example ranging from 0.01 to 10.0 mass %, are introduced into said dermatic. For a short while, said dermatic is present on the surface of the horny layer of the skin in an aerobic condition thereof without having any time to harmfully affect the microflora thereof, the remainder of the dermatic being easily washed out of the skin surface. The main mass of the dermatic being embodied in the liposomal form penetrates the epidermis of the skin, whereby the bactericide effect of dioxidine is increased by 10-30 times in an aerobic condition and produces a prolonged and maximal action on the microflora within the thickness of the skin and branches thereof, protecting them against a pyoinflammatory process occurring from the inside. Said invention increases the efficiency of antibacterial agents and reduces the harmful action thereof on the useful resident microflora of the skin.
FIELD: biotechnology. SUBSTANCE: method involves milling and extraction of cock crests with water followed by isolation of the end product. Extraction is carried out for three stages at ratio raw and water = 1:(4-6) for 2-4 h. Extracts were combined and treated with trichloroacetic acid at amount 1-2% of extract volume, defatted and the formed deposit is dehydrated with acetone and ether. Deposit is dissolved in water (2-4 volumes to raw mass) and 0.2-0.4 vol. p. tea extract is added to 1 vol. p. solution. Tea extract is obtained by infusion of 1 mas. p. the dried tea leaves with 80-100 vol. p. p. water at 95-100 C for 5-10 min followed by mixture keeping at 40-60 C for 1-2 h, filtration and solvent drying. Product is used in medicine for treatment diseases caused by different microorganisms. EFFECT: improved method of preparing.
Conventional DLI has invariably been associated with high rates of severe graft-versus-host disease (GVHD) and GVHD-related non-relapse mortality (NRM). Thus, in our previous studies, the DLI procedure has been modified to use G-CSF-mobilized peripheral blood stem cells (PBSCs) instead of steady-state lymphocytes. G-CSF mobilization results in the modulation of the polarization potential of T cells from Th1 to Th2. In addition, T-cell hyporesponsiveness is induced via the proliferation of dendritic cell 2 and monocytes and the down-regulation of CD28/B7. Furthermore, G-CSF augments NK-T-cell-dependent CD8+ cytotoxicity. These data constructed the rationale for the use of G-CSF-primed peripheral blood DLI to reduce DLI-associated GVHD and enhance the GVT effect of DLI. To date, there is no effective target therapy for acute leukemia with gene mutations such as DNMT3A, TET2 and TP53 and their response to chemotherapy and survival even after allogenic stem cell transplantation remains poor. Hypomethylating agents were reported to reverse the repression of HLA molecules and cancer testis antigens on leukemia cells, rendering them more sensitive to anti-leukemic activity mediated by DLI. The use of low-dose decitabine after allogenic stem cell transplantation was safe for early hematopoietic reconstitution. Therefore, decitabine was planned to be given prior to prophylactic DLI in the current study.
The invention discloses a traditional Chinese medicinal composition for treating qi-yin deficiency type chronic glomerulonephritis. The traditional Chinese medicinal composition is characterized by being prepared from the following medicinal materials in parts by weight: 10-15 parts of radix adenophorae, 20-25 parts of selenitum, 9-12 parts of radix polygonati officinalis, 6-9 parts of dry root tuber of Pseudostellaria maximowicziana (Franch.et Sav.)Pax ex Pax et Hoffm.[Krascheninikowia maximowicziana Franch.et Sav.], 12-15 parts of root of dunn antictrema, 12-15 parts of herba oreatis martianae, 25-30 parts of rhizome of Rehmannia chingii Li, 25-30 parts of emblic leafflower fruits, 6-9 parts of rhizome of Iris wilsonii C. H. Wright, 15-20 parts of root of gymnema foetidum tsiang, 20-25 parts of herba limonii bicoloris, 12-15 parts of Aculeate Staff-tree, 20-25 parts of root tuber of Habenaria tentaculata Reichb. f., and 6-9 parts of honey-fried licorice root. The traditional Chinese medicinal composition is high in effective rate and reliable in curative effect when used for treating qi-yin deficiency type chronic glomerulonephritis, and the relapse seldom occurs after the qi-yin deficiency type chronic glomerulonephritis is radically treated.
PURPOSE:To improve the shelf stability and safety of the title emulsion composition by incorporating a granular body having 0.01-5mum mean particle diameter and with the surface modified with an alcoholic hydroxyl group and/or a polyoxyalkylene group to prepare the emulsion composition. CONSTITUTION:The powdery body is firstly coated with the silicon polymer having an Si-H group, and then an unsaturated compd. having an alcoholic hydroxyl group or a polyoxyalkylene group is added to the Si-H group to produce the powdery body having 0.01-5mum mean particle diameter and with the surface modified with an alcoholic hydroxyl group and/or a polyoxyalkylene group. The surface-modified powdery body, oil, water, and a surfactant, as required, are mixed to prepare the emulsion composition. The content of the surface-modified powdery body in the emulsion composition is appropriately controlled to 0.5-20wt.%. Talc, kaolin, calcium carbonate, etc., are used as the powder for surface modification.
INTRODUCTION: Emotional eating is a situation with harmful consequences for the physical, mental and social health of humans. In this regard, the present study aimed to explain the role of social culture in the lived experiences of emotional eating in Iranian obese women.
METHODS: This was a qualitative study conducted using the phenomenological approach. Purposive heterogeneous sampling method was used to select 17 women with body mass index of 30 and above who had emotional eating experience. Data were collected through semi-structured and face-to-face interviews. A guideline designed by the research team, whose content validity was confirmed by the expert panel, was used to conduct the interviews. Data were analyzed based on Diekelmann 7-step approach, and trustworthiness was evaluated by Lincoln and Guba criteria.
RESULTS: The main topic of the findings was social culture and emotional eating, which was explained by three themes: "influence of social culture", "language culture of eating" and "the culture of eating together". Influence of social culture had three sub-themes: "a legal and popular entertainment", "hospitality culture: encouraging guests to overeat", and "coping with the social stigma of thinness and obesity". The language culture of eating had two sub-themes of "association of common infinitives" and "the symbol of swallowing anger ". Also, "culture of eating together" included 2 sub-topics with the titles "pleasant symbol of belonging and love" and "the symbol of family cohesion".
CONCLUSION: This study found that social culture through language, norms, and customs can initiate and/or reinforce emotional eating. The results of this study can be used in the design of interventions to improve emotional eating behavior in women by emphasizing the characteristics of Iranian social culture.
PURPOSE: We present a case of an ischemic retinopathy with severe vision loss secondary to a childhood stroke.
METHODS: Case report.
RESULTS: An otherwise healthy 9-year-old girl presented with a 1-day history of impaired gait and speech. After performing computed tomography and magnetic resonance imaging, thrombosis of the left internal carotid artery was observed and a diagnosis of ischemic stroke was established. Serological autoimmune, coagulation, and viral panels were unrewarding. Cardiac, inflammatory, and coagulation disorders were ruled out. The cause was attributed to a focal cerebral arteriopathy, a common cause of childhood stroke. The patient was treated with mechanical thrombectomy followed by anticoagulation. The day after, the patient referred vision loss of 20/100 in the left eye. Fundus evaluation of the left eye depicted diffuse intraretinal hemorrhages and cotton-wool spots and there was retinal whitening at the posterior pole. Six weeks after, VA dropped to counting fingers.
CONCLUSION: A macular optical coherence tomography revealed diffuse atrophic changes in the inner retinal layers at the macula, and the angio-optical coherence tomography showed an enlarged foveal avascular zone. We propose ischemia-reperfusion as the primary explanation of this unusual event.
PURPOSE:To produce a new compound and its pharmaceutically permissible salt, easily producible from gallic acid, having low toxicity, high safety and excellent anticancer action, especially effective for hepatic cancer and useful as an anticancer agent. CONSTITUTION:A compound of formula (R1 to R3 are H or alkyl; R4 is O, S or NH) and its pharmaceutically permissible salt, e.g. 3,4-methylenedioxyphenyl 3,4,5-trihydroxybenzoate. The compound of formula can be produced by protecting gallic acid e.g. by methoxymethylation, hydrolyzing the protected gallic acid to carboxylic acid, condensing the acid with disesamol, 3,4- methylenedioxyaniline, etc., to obtain ester, amide or thioester and deprotecting the product. The compound of formula exhibits extremely high activity compared with gallic acid and has improved absorbability.
BACKGROUND: Leaf rust (LR) is among the most destructive fungal diseases of rye (Secale cereale L.). Despite intensive research using various analytical and methodological approaches, such as quantitative trait locus (QTL) mapping, candidate gene expression analysis, and transcriptome sequencing, the genetic basis of the rye immune response to LR remains unclear.
RESULTS: A genome-wide association study was employed to detect QTLs controlling the immune response to LR of rye. A mapping population, G38A, was constructed by crossing two inbred lines: 723 (susceptible to LR) and JKI-NIL-Pr3 (a donor of the LR resistance gene Pr3). For genotyping, SNP-DArT and silico-DArT markers were used. Resistance phenotyping was conducted by visual assessment of the infection severity in detached leaf segments inoculated with two isolates of Puccinia recondita f. sp. secalis, namely, 60/17/2.1 (isolate S) in the main experiment and 86/n/2.1_5x (isolate N) in the validation experiment, at 10 and 17 days post-infection (dpi), respectively. In total, 42,773 SNP-DArT and 105,866 silico-DArT markers were included in the main analysis including isolate S, of which 129 and 140 SNP-DArTs and 767 and 776 silico-DArTs were significantly associated (p ≤ 0.001; - log10(p) ≥ 3.0) with the immune response to LR at 10 and 17 dpi, respectively. Most significant markers were mapped to chromosome 1R. The number of common markers from both systems and at both time points occupying common chromosomal positions was 37, of which 21 were positioned in genes, comprising 18 markers located in exons and three in introns. This gene pool included genes encoding proteins with a known function in response to LR (e.g., a NBS-LRR disease resistance protein-like protein and carboxyl-terminal peptidase).
CONCLUSION: This study has expanded and supplemented existing knowledge of the genetic basis of rye resistance to LR by (1) detecting two QTLs associated with the LR immune response of rye, of which one located on the long arm of chromosome 1R is newly detected, (2) assigning hundreds of markers significantly associated with the immune response to LR to genes in the 'Lo7' genome, and (3) predicting the potential translational effects of polymorphisms of SNP-DArT markers located within protein-coding genes.
BACKGROUND: Smell loss significantly impacts the quality of life in patients. However, there is limited research on smell loss in individuals with amyotrophic lateral sclerosis (ALS), and the correlation between smell loss and cognitive impairment is unclear. This study aimed to investigate the correlation between smell loss and cognition impairment in ALS patients.
METHODS: The study included 216 ALS patients. The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) and smell identification test specifically for the Chinese population (CSIT) were administered to evaluate participants' cognitive and olfactory function, respectively.
RESULTS: After covarying for age, sex, BMI, education level, degree of hunger, dietary bias, eagerness for food, stress, smoking status, alcohol consumption, and upper respiratory tract infection (URTI) or rhinitis, CSIT scores were significantly correlated with ECAS scores (r = 0.162, p = 0.028), especially the ALS-specific scores (r = 0.158, p = 0.031). Even after excluding patients with URTI or rhinitis, the results were similar. CSIT scores were significantly correlated with ECAS scores (r = 0.224, p = 0.011), especially the ALS-specific scores (r = 0.205, p = 0.019).
CONCLUSION: In patients with ALS, smell loss is significantly correlated with cognitive impairment, particularly frontotemporal dysfunction. Cognitive dysfunction may lead to worse olfactory performance in ALS patients.
A method for modulating an immune response comprises contacting in vitro a cell expressing B7-4 or an immune cell expressing PD-1 with an agent that modulates the interaction of B74 with PD-1 to thereby modulate the immune response. The agent is selected from an activating antibody that recognizes PD-1 and transmits a negative signal via PD- 1; an antibody that recognizes PD-1 a polypeptide comprising an extra cellular domain of SEQ ID NO:2 or SEQ ID NO:4 in multivalent form; a polypeptide comprising an amino acid sequence encoded by a nucleic aid molecule that hybridizes under stringent conditions to the complement of nucleotides encoding amino acids 19-245 of SEQ ID NO:2 or amino acids 19-238 of SEQ ID NO:4 in multivalent form; an antibody that recognizes PD-1 and doesn't transmit an negative signal, a soluble form of B7-4 and an antibody that recognizes B7-4 and a soluble form of PD-1. Also described is a composition that comprises and antigen and the agent as described above, and a assay for screening for compounds that modulate the binding and/or activity of B7-4 and PD-1. An agent that modulates the interaction off PD-1 and B7-4 such that a negative signal is not transmitted via PD-1 can be used in the manufacture of a medicament for treating a subject having a condition that would benefit from up regulation of a immune response. Preferably the condition is a tumor, a neurological disease or an immunosuppressive disease. An agent that modulates the interaction off PD-1 and B7-4 such that a negative signal is transmitted via PD-1 can be used in the manufacture of a medicament for treating a subject having a condition that would benefit from down regulation of an immune response. Preferably the condition is selected from a transplant, an allergy and an autoimmune disorder.
Enteroviruses have been associated with type 1 diabetes in several studies. Enterovirus infections may either increase or decrease the risk of type 1 diabetes depending on the age of infection and the type of enterovirus in question. There is remarkable homology between the structure of poliovirus and other enteroviruses. It has been shown in previous studies that the T-lymphocytes recognize these structures and cross-react with different enterovirus serotypes. Our hypothesis is that polio vaccination induces a cross-reacting T-cell response which strengthens enterovirus immunity and thus accelerate the elimination of the enterovirus infections. We evaluated whether early serial live enterovirus vaccine (oral polio vaccine, OPV) can influence the enterovirus immunity and initiation of islet autoimmunity in young genetically predisposed children.

This study was carried out in the birth cohort of the ongoing Diabetes Prediction and Prevention (DIPP) study in Finland. All the children carried HLA-DQ genes conferring moderately increased risk for type 1 diabetes (HLA DQB1\*0302/x, x≠ DQB1\*0201, \*0301, \*0602). Sixty-four children (34 males) were given doses of OPV (Polio Sabin®, SB Biologicals, Rixensart, Belgium) at the age of 2, 3, 6 and 12 months during the years 1999-2000 (two drops per os in each dose). This vaccine includes attenuated replication competent strains of the three poliovirus types (polioviruses 1, 2, 3) leading to infection in vaccinated children. The control group comprising 251 children received inactivated poliovirus vaccine (IPV) at the age of 6 and 12 months according to the national immunization protocol in Finland at that time. After the age of 12 months both groups were recommended to continue the national immunization program with IPV vaccine.

All children were followed regularly from birth with blood samples taken at 3-12 months interval for detection of type 1 diabetes-associated autoantibodies in serum including insulin autoantibodies (IAA), islet cell cytoplasmic antibody (ICA), insulinoma-associated protein 2 antibodies (IA-2A) and GAD antibodies (GADA) (5-7). Stool samples were collected monthly at the age of 2-24 months and systematically screened for the presence of enterovirus and using RT-PCR.
The proposed study will evaluate, via a randomized controlled trial, the incremental utility of I-PCIT for disruptive behavioral problems in traditionally underserved young children with developmental delay (DD) from predominantly economically disadvantaged and ethnic and racial minority backgrounds. Specifically, the investigators are interested in the impact of I-PCIT on child disruptive behavior problems, parenting practices, parental distress, and pre-academic skills relative to traditional referrals as usual (RAU) among youth aging out of Part C EI services and transitioning from home-based family services to school-based special education services. A secondary goal is to evaluate potential moderators and mediators that explain under which circumstances, for whom, and through which pathways I-PCIT is most effective for young children with DD. Our primary aims are (1) to evaluate the immediate and one-year impact of I-PCIT on (1a) disruptive behavior problems in young children with DD, as well as (1b) parenting practices and (1c) parental distress in parents of young children with DD; (2) to evaluate the impact of I-PCIT on pre-academic skills among young children with DD; and (3) to evaluate (3a) family retention, (3b) engagement, and (3c) satisfaction associated with I-PCIT in young children with DD. Our secondary aim is to examine potential moderators and mediators of response to I-PCIT for disruptive behavior problems in young children with DD. Specifically, the investigators are interested in the extent to which technological literacy and access (4a) moderate I-PCIT efficacy, such that I-PCIT efficacy will be weaker among families with poorer technological literacy and/or access, and the extent to which traditional barriers to care (4b) moderate I-PCIT efficacy, such that the incremental efficacy of I-PCIT over RAU will be strongest among families with geographic, transportation and/or childcare obstacles to in-person services. Finally, the investigators hypothesize that I-PCIT will yield changes in child behavior and pre-academic skills indirectly through direct effects on parenting practices (4c). Specifically, changes in parental consistency, warmth, follow-through, and effective discipline will mediate observed I-PCIT efficacy, such that these treatment-related parenting changes will account for observed differences in child disruptive behavior problems and pre-academic skills.
<P>PROBLEM TO BE SOLVED: To treat the disorders (particularly cancers) considered to be caused by abnormal immune responses.  <P>SOLUTION: Dendritic cells (DC) play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states including cancer. The method includes decreasing the responsiveness to activation stimuli by diseases by stimulating dendritic cells from the host. In particular, methods are provided for treating cancer in a mammal comprising administering to the mammal an effective amount of a tumor-derived DC inhibitory factor antagonist in combination with an effective amount of a Toll-like receptor (TLR) agonist.  <P>COPYRIGHT: (C)2010,JPO&INPIT